Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial
- Rivista
- LANCET ONCOLOGY
- Autori
- Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, Tiseo M, Parra HS, Grossi F, Cappuzzo F, De Marinis F, Pedrazzoli P, Bonomi M, Gianoncelli L, Perrino M, Santoro A, Zanelli F, Bonelli C, Maconi A, Frega S, Gervasi E, Boni L, Ceresoli GL
- Citazione bibliografica
- 2021 Sep 6;S1470-2045(21)00404-6
- DOI
- 10.1016/S1470-2045(21)00404-6
- Unit di ricerca
- Mesotelioma